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The CARD11-BCL10-MALT1 (CBM) complex triggers the adaptive immune response in
lymphocytes and lymphoma cells. CARD11/CARMA1 acts as a molecular seed inducing
BCL10 ﬁlaments, but the integration of MALT1 and the assembly of a functional CBM
complex has remained elusive. Using cryo-EM we solved the helical structure of the BCL10-
MALT1 ﬁlament. The structural model of the ﬁlament core solved at 4.9 Å resolution iden-
tiﬁed the interface between the N-terminal MALT1 DD and the BCL10 caspase recruitment
domain. The C-terminal MALT1 Ig and paracaspase domains protrude from this core to
orchestrate binding of mediators and substrates at the ﬁlament periphery. Mutagenesis
studies support the importance of the identiﬁed BCL10-MALT1 interface for CBM complex
assembly, MALT1 protease activation and NF-κB signaling in Jurkat and primary CD4 T-cells.
Collectively, we present a model for the assembly and architecture of the CBM signaling
complex and how it functions as a signaling hub in T-lymphocytes.
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The immune stimulation of B-cell and T-cell receptors (TCRand BCR), as well as activating natural killer cell and fungalrecognition receptors triggers activation of distinct Caspase
recruitment domain (CARD)-containing scaffold proteins,
including CARD9, CARD10 (also known as CARMA3), CARD11
(CARMA1), and CARD14 (CARMA2)1,2. CARD11, B cell lym-
phoma 10 (BCL10) and mucosa-associated lymphoid tissue lym-
phoma translocation protein 1 (MALT1) assemble the CARD11-
BCL10-MALT1 (CBM) complex that bridges TCR/BCR proximal
signaling to the canonical IκB kinase (IKK)/NF-κB and JNK
pathway in lymphocytes3. Upon assembly, the CBM complex
serves as a scaffolding platform that activates downstream sig-
naling events via association of mediators such as ubiquitin ligases
(e.g., TRAF6) and protein kinases (e.g., TAK1 and IKKβ)4–6.
Upon activation, IKKβ phosphorylates IκBα leading to its pro-
teasomal degradation and subsequent release, nuclear transloca-
tion and transcriptional activation of NF-κB7. Beyond the
scaffolding function, MALT1 is a paracaspase and contributes
proteolytic activity to the CBM complex, which is key for optimal
lymphocyte activation and differentiation8–10. Altogether, CBM
complex downstream pathways play important roles in regulating
the activation, proliferation, and effector functions of lymphocytes
in adaptive immunity11.
The pathological relevance of CARD11, BCL10, and MALT1 is
demonstrated by germline loss-of-function mutations associated
with combined immunodeﬁciency (CID)12–17. In contrast, acti-
vating mutations in CARD11 promote B-cell proliferation and
are frequently found in the malignant activated B-cell-subtype of
diffuse large B-cell lymphoma (ABC DLBCL)18–20. Furthermore,
chromosomal translocations leading to overexpression of BCL10
or MALT1 as well as generation of the API2-MALT1 fusion
protein result in oncogenic activation associated with MALT
lymphoma21–23. The clinical impact of the CBM signalosome has
been emphasized by the discovery of MALT1 protease inhibitors
that suppress antigen responses in T-cells and kill ABC DLBCL
cells that arise from chronic BCR signaling24–26.
In resting T-cells CARD11 is kept in an inactive conformation
that is activated through phosphorylation by protein kinases
including PKCθ and PKCβ27,28. In the hyper-phosphorylated
conformation BCL10-MALT1 complexes are recruited via het-
erotypic interaction of the CARD11 and BCL10 CARD
domains29,30. CARD11 acts as a molecular seed that upon
binding induces the assembly of BCL10 ﬁlaments in vitro and in
cells31,32. While the cryo-EM structure of the BCL10 ﬁlaments
has been recently determined31, no structural information is
available for the integration of MALT1 into the BCL10 ﬁlaments.
MALT1 constitutively associates with BCL10 in vitro and in cells.
Mutational analyses suggested that regions in the C-terminal Ser/
Thr-rich region of BCL10 interact with the N-terminal death
domain (DD) and the two Ig (immunoglobulin)-like domains
(Ig1/Ig2) of MALT133–36. Nevertheless, the detailed nature of the
BCL10-MALT1 interface remains unresolved.
To gain further inside into the CBM complex assembly we
determined the cryo-EM structure of the BCL10-MALT1 com-
plex. Our data deﬁne the exact interfaces for BCL10 oligomer-
ization as well as the interaction of BCL10 CARD and MALT1
DD. Reconstitution assays of either KO Jurkat T-cells or murine
CD4 T-cells from MALT1−/− mice highlight the signiﬁcance of
the interaction sites for CBM complex formation and activation
of all CBM downstream signaling events.
Results
Cryo-EM structure of the BCL10-MALT1 ﬁlament. To provide
structural information about the interaction of BCL10 with
MALT1 we performed cryo-electron microscopy (cryo-EM) of
the human BCL10 (full length)-MALT1 (T29-G722) complex
(Fig. 1a). BCL10 and MALT1 were co-expressed in bacteria and
formed a stoichiometric complex that was puriﬁed to near
homogeneity (Supplementary Fig. 1a). A cleavable GST-fusion at
the N-terminus of BCL10 prevented ﬁlament assembly during
puriﬁcation and proteolytic removal of the GST-tag initiated
oligomerization to a particle size of ~100 nm as determined by
dynamic light scattering (DLS) (Supplementary Fig. 1b). An
in vitro MALT1 cleavage assay revealed that the BCL10-MALT1
complex possesses protease activity (Supplementary Fig. 1c).
Visual inspection of cryo-EM images of the puriﬁed complex,
underpinned by 2D classiﬁcation and examination of the power
spectra, revealed that BCL10-MALT1 assembles into ﬂexible
helical ﬁlaments of ~29 nm in diameter, with an ordered inner
core of ~14 nm in diameter and a less deﬁned periphery
(Fig. 1b–d). To calculate the high-resolution structure of the
ﬁlament interior, the data were processed while limiting the
diameter to 21 nm. This analysis was performed on the very ﬁrst
image frames 2–7 (total dose 14 electrons/Å2) to avoid sample
and image quality deterioration due to radiation damage. This
resulted in a 4.9 Å resolution map of BCL10 CARDs tightly
decorated by MALT1 DD (Fig. 1e–g).
Our analysis revealed that BCL10-MALT1 is a left-handed
helix with a per subunit rotation of 100.8° and a rise of 5.083 Å,
resulting in 3.571 subunits of BCL10-MALT1 per helical turn.
This helical arrangement agrees with the one observed for the
BCL10 (residue 1–115) ﬁlament alone, thus indicating that the
overall arrangement of the BCL10 CARD core is largely unaltered
within the BCL10-MALT1 complex structure (Fig. 2a–f)31,32. The
4.9 Å resolution map of the inner ﬁlament part enabled us to
build a pseudo atomic model of BCL10 residues 10–115 and
MALT1 residues (30–121) by ﬂexible ﬁtting of a BCL10
homology model and a related crystal structure of MALT1 DD
into the EM density (Fig. 1h, i). Interestingly, the structural
comparison with the MALT1 DD X-ray structure (pdb ID: 2G7R)
reveals that in the presented EM density helix α6 is kinked and
not forming an extended helix as previously proposed37. The
observed fold of the kinked MALT1 helix is similar to other
CARD family members (Fig. 1i).
BCL10 ﬁlament assembly is critical for CARD11 recruitment.
The BCL10 CARD structure is considerably stabilized in
comparison to the NMR structure due to the extensive network
of interactions within the BCL10-MALT1 ﬁlament assembly
(Fig. 2). To obtain a clearer perception of potential rearrange-
ments of BCL10 upon interaction with MALT1, we compared
the model of the BCL10 ﬁlaments alone, with our model of
BCL10 in the BCL10-MALT1 complex31. Thereby, we found
differences speciﬁcally in the amino acid registry that led to
altered assignments of key residues involved in BCL10-MALT1
interaction (Supplementary Fig. 2a). Based on the reﬁnement
statistics and the FSC (Fourier Shell Correlation) curves
assessing the ﬁt between the maps and the models, our model is
consistent with both our and the published EM densities31 and
provides reasonable stereochemistry and geometry values
(Supplementary Fig. 2b).
The identiﬁed BCL10 CARD-CARD interfaces, type I, II, and
III as diagrammed in Fig. 2a–f have been previously reported and
are shown here to illustrate the composition of the BCL10 core
ﬁlament31. The individual residues involved in the three types of
interactions, in the presented structure are highlighted in
Fig. 2d–f. Whereas type I and type II interactions are interstrand
contacts between the helical turns (Fig. 2c–e), the type III
interface exhibits interactions in the helical-strand direction
(Fig. 2f). All interfaces identiﬁed by the BCL10 ﬁlament alone are
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largely conserved within the BCL10-MALT1 complex within the
resolution limit of both structures31,32 (Fig. 2d–f). Thereby, the
type I interface comprises the most extensive interactions, with
high electrostatic surface complementarity (Fig. 2d). Additionally,
we identiﬁed residue R42 in interface I and R36 in interface II to
be important for BCL10 ﬁlament assembly (Fig. 2d, e). To
validate the importance of the interfaces we generated site-
directed mutants and compared their capability to oligomerize
in vitro with those of the wild-type complex. The BCL10
mutations R42E, R49E, and R36E abrogated the ability of the
BCL10-MALT1 complex to oligomerize, while the interaction
with MALT1 was retained as shown by DLS and co-puriﬁcation,
respectively (Supplementary Fig. 2c, d). This emphasizes the
relevance of the identiﬁed interaction regions for ﬁlament
assembly but not MALT1 interaction.
Previously, the effect of BCL10 interface I-III mutants on NF-
κB and MALT1 activation was analyzed upon overexpression32.
Since ﬁlament assembly with recombinant puriﬁed BCL10-
MALT1 is strongly inﬂuenced by local protein concentration,
we aimed to investigate the biological effects of BCL10
oligomerization mutants in a clean genetic setting without
overexpression or perturbation by endogenous BCL10. To this
end we generated BCL10 KO Jurkat T-cells by CRISPR/Cas9
technology using sgRNA targeting Exon1 of human BCL10
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Fig. 1 Cryo-EM reconstruction and atomic model of the BCL10-MALT1 ﬁlament. a Domain organization of the BCL10 and MALT1 protein constructs.
b Example cryo-EM micrograph of the BCL10-MALT1 complex ﬁlaments. c, d 2D class averages and corresponding power spectra of BCL10-MALT1
ﬁlaments used for helical parameter determination. e, f Overall architecture of the BCL10-MALT1 ﬁlament assembly shown together with the cryo-EM
density, clipped top and side view, respectively. The map shows the inner well-structured part of the ﬁlament at an overall resolution of 4.9 Å (FSC curve
see Supplementary Fig. 8a). This part consists of the BCL10 CARD (residues 10–115) and the MALT1 DD (residues 30–121) colored blue and orange,
respectively. g, h Example parts of the cryo EM density map shown together with the BCL10-MALT1 DD and the atomic model of BCL10 shown in ribbon
and stick representation, respectively. i Overlay of the MALT1 DD cryo-EM and crystal structure (pdb ID: 2g7r) colored orange and beige, respectively
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(Supplementary Fig. 3a). After limiting dilution, we obtained a
BCL10 KO Jurkat T-cell clone, which was reconstituted with
BCL10 wt or the BCL10 interface I (R42E) and II (R36E) mutants,
which lost the ability to assemble ﬁlaments in vitro. To exclude
that the cellular effects are due to overall conformational
alterations in the BCL10 CARD, by changing positively charged
arginines to negatively charged glutamic acids, we included the
less severe BCL10 R42A substitution (Fig. 3b). Lentiviral infection
led to homogenous transduction of Jurkat T-cells as judged by co-
expressed surface marker ΔCD2 and equivalent expression of all
constructs close to endogenous levels in the BCL10 KO cells
(Supplementary Fig. 3b–e). Precipitation of BCL10 either by co-
IP or StrepTactin pull-down (ST-PD) demonstrated that the
mutation in the BCL10 ﬁlament interfaces I and II prevented the
PMA/Ionomycin (P/I) inducible recruitment of BCL10 to
CARD11 and thus stimulus-dependent CBM complex formation
(Fig. 3a, b). However, none of the mutants impaired constitutive
binding of BCL10 to MALT1, suggesting that the overall protein
structure is still intact.
To determine the functional relevance of the BCL10–BCL10
interfaces for T-cell signaling, we stimulated the Jurkat T-cells
expressing the distinct BCL10 mutants and analyzed NF-κB
signaling and MALT1 protease activation (Fig. 3c, d). Indeed,
interface I mutations BCL10 R42E or R42A and interface II
mutation R36E completely abolished IκBα phosphorylation and
degradation as well as NF-κB DNA binding after P/I stimulation.
Likewise, activation of the MALT1 protease was absent in all
BCL10 ﬁlament mutants as determined by the ability to cleave the
substrates BCL10, CYLD, and HOIL1 (Fig. 3c, d). Hence, under
physiological conditions the correct assembly of the BCL10 core
ﬁlament via its CARDs is crucial for stimulus-dependent
CARD11 recruitment and thus CBM complex assembly and
downstream functions.
MALT1 binds to BCL10 via DD and CARD interaction. Besides
unravelling the architecture of the BCL10 CARD ﬁlaments, the
4.9 Å resolution cryo-EM map provides the detailed molecular
structure of the BCL10-MALT1 interaction surface (Fig. 4a–c).
The MALT1 DD interacts with BCL10 at the rim of the CARD
core ﬁlament in a 1:1 stoichiometry. Thereby, the C-termini of
MALT1 DD domains are pointing away from the core ﬁlament. A
close-up view of the BCL10-MALT1 interaction site I (BM-I)
illustrates that MALT1 binds to the C-terminal part (BCL10 helix
α6) of the BCL10 CARD forming a new interface that is distinct
from the BCL10 ﬁlament interfaces I–III (Fig. 4a–c). Thus, the
structure underscores that BCL10 ﬁlament assembly is not
required for MALT1 association, which agrees with the cellular
pre-assembly of the BCL10-MALT1 complex without stimulation
(see Fig. 3a, b). In BM-I, the two most central interacting residues
of MALT1 are V81 and L82 situated in helix α4 (Fig. 4c). The
opposing hydrophobic surface in BCL10 is formed by L104, V103
in helix α6 and V83 and I96 in helices α5 and α6, respectively.
Several salt bridges stabilize the hydrophobic core contacts
(Fig. 4c).
To investigate the signiﬁcance of the identiﬁed BM-I, we
mutated residues on both sides of the interface. Co-puriﬁcation of
GST-BCL10 demonstrates a severely reduced binding of MALT1
V81R mutant in vitro (Supplementary Fig. 4a). In line, the single
mutation V81R completely disrupted the interaction of BCL10
after co-expression in HEK293 (Fig. 4d). Vice versa, BCL10
L104R abolished association of MALT1 to BCL10 (Fig. 4d).
Further, the cryo-EM structure indicated a potential second
interface between MALT1 DD α4 and α5 segment and the
adjacent BCL10 helix α6 at the C-terminus of the core CARD
ﬁlament (BM-II; Supplementary Fig. 4b, c). However, mutation of
potential contact points Q76A/E98R as well as the putative
disulﬁde bond C77-C91 (C77A) in MALT1 did not affect BCL10-
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MALT1 association in co-IPs (Supplementary Fig. 4d), suggesting
that BM-II is not essential for BCL10-MALT1 complex
formation.
CBM assembly and T-cell activation relies on MALT1 binding.
To assess the biological impact of the newly identiﬁed BCL10-
MALT1 interaction surfaces, we expressed BM-I mutants located
on both sides of the interface in BCL10 or MALT1 KO T-cells,
respectively (Fig. 5). MALT1 KO Jurkat T-cells were generated by
CRISPR/Cas9 technology38. In BCL10 we used the single muta-
tion L104R in helix α6 of the CARD. In MALT1 we analyzed
mutation V81R or L82D in α4 of the DD opposite to the BCL10
α6 helix. Using lentiviral transduction, we obtained Jurkat T-cells
that expressed all BCL10 or MALT1 constructs homogenously at
endogenous levels (Supplementary Fig. 5a-f). Indeed, BCL10 co-
IP experiments revealed that missense mutation either in BCL10
(L104R) or MALT1 (V81R or L82D) completely abrogate the
constitutive binding of BCL10 to MALT1 in resting Jurkat T-cells
(Fig. 5a–c). For BCL10 L104R and MALT1 V81R, loss of inter-
action was also conﬁrmed by ST-PD of BCL10 or MALT1,
respectively (Supplementary Fig. 5g-h). Moreover, loss of MALT1
led to a severely reduced BCL10 recruitment to CARD11 after P/I
stimulation (Fig. 5b, c). In all BCL10 and MALT1 interface
mutants the binding of BCL10 to CARD11 was impaired, pro-
viding evidence that the constitutive association of BCL10 and
MALT1 is a prerequisite for CBM complex assembly (Fig. 5a–c).
Thus, in T-cells the BCL10-MALT1 interaction signiﬁcantly
contributes to the dynamics of CBM complex formation
strengthening the importance of interface BM-I.
To determine the functional relevance of the BCL10-MALT1
interface for T-cell signaling and MALT1 activation, we
stimulated the Jurkat T-cells expressing the MALT1 and BCL10
BM-I mutants (Fig. 5d–h). In line with its critical role for
assembly of the entire CBM complex, IκBα phosphorylation/
degradation and NF-κB DNA binding after T-cell stimulation
were abolished. Also, activation of the MALT1 protease was
absent in the BCL10 L104R (Fig. 5d, e) as well as MALT1 V81R
(Fig. 5f, g) or MALT1 L82D (Fig. 5h) mutants, as evident from
the lack of substrate cleavage. In contrast, BM-II mutations
Q76A/E98R and C77A, which did not signiﬁcantly impair
BCL10-MALT1 association, did not alter NF-κB responses
(Supplementary Fig. 4d and 5i). To address the importance of
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the BCL10-MALT1 interface BM-I for T-cell activation in a
physiological setting, we puriﬁed CD4 T-cells from MALT1−/−
mice and reconstituted the cells with either MALT1 wt or the
MALT1 BM-I mutant V81R. Effects on NF-κB signaling and IL-2
production after MALT1 reconstitution were determined by
single cell FACS analyses. Retroviral transduction led to equal
expression of MALT1 wt and the mutant construct V81R in
primary T-cells (Fig. 5i). Infected cells were identiﬁed by the
surface marker Thy1.1 (Supplementary Fig. 6a-b). As expected,
IκBα was not degraded and IL-2 was not signiﬁcantly induced in
Thy1.1-negative MALT1−/− T-cells (Supplementary Fig. 6a-b).
When gated on the transduced Thy1.1-positive CD4 T-cells
population, MALT1 wt but not BM-I interface mutant V81R was
able to rescue NF-κB signaling after P/I stimulation as evident
from IκBα degradation (Fig. 5j). Further, strong upregulation of
IL-2 in response to P/I stimulation or anti-CD3/CD28 co-ligation
in CD4 T-cells was impaired in the MALT1 V81R mutant
expressing cells as determined by intracellular FACS staining
(Fig. 5k, l). Thus, the identiﬁed BCL10-MALT1 interface I is
essential for bridging TCR stimulation to downstream signaling
and T-cell activation.
Architecture of the BCL10-MALT1 holo-complex. To gain
more information about the structural organisation of the addi-
tional MALT1 domains (Ig1-Ig2-paracaspase-Ig3) around the
BCL10-MALT1 DD skeleton, the cryo EM data have been ana-
lysed by a second approach. The diameter constraints have been
relieved to 29 nm and the dose increased to 32 electrons/Å2
(frames 2–16) which yielded an overall 5.9 Å, but highly aniso-
tropic resolution reconstruction of the entire BCL10-MALT1
complex domains (Fig. 6 and Supplementary Fig. 8). In the
density ﬁltered to 6 Å the MALT1 DDs are rigidly attached to the
BCL10 core (Fig. 6a, b). The EM density ﬁltered to 8 Å depicts
that the subsequent MALT1 domain Ig1 is clearly visible and we
were able to rigid body dock this domain. The Ig1 domain is
pointing away from the BCL10-MALT1 DD core ﬁlament
separating the C-terminal domains from the inner core of the
ﬁlament (Fig. 6c, d). Together with the ﬂexible linked Ig2 domain
this arrangement supposedly allows for dimerization of the
MALT1 paracaspase domains, which is key for MALT1 protease
activation39. Further, the map with a resolution cut-off at 25 Å
indicates how a stable inner core formed by BCL10 CARD and
the MALT1 DD-Ig1 fragments orchestrates a ﬂexible outer
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analyzed by WB for co-precipitation
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MALT1 platform (Fig. 6e, f). The top view illustrates a ‘paddle
wheel-like’ architecture of the BCL10-MALT1 complex with the
MALT1 Ig1-Ig2-paracaspase domains forming the more adap-
table periphery of the ﬁlament (Fig. 6f). Due to the ﬂexibility of
the C-terminal MALT1 domains, we could not provide an
unambiguous ﬁt of the MALT1 Ig2-paracaspase-Ig3 domains.
Discussion
Our cryo-EM structure resolved the inner core of the BCL10-
MALT1 assembly at 4.9 Å resolution. We identiﬁed the BCL10
CARD and MALT1 DD interface BM-I and cell-based assays
provide compelling proof that the ﬁlaments channel all CBM
downstream signaling events. Since the peripheral C-terminal
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regions of MALT1 and BCL10 are ﬂexible, it is unlikely that
other surfaces are directly contributing to BCL10 binding. This is
remarkable, because previous co-IPs using overexpression sug-
gested that BCL10-MALT1 may associate through a more
extended binding surface. BCL10-MALT1 interaction was lost by
a small deletion at the C-terminus of the CARD (aa 106–120),
which overlaps the MALT1 binding surface that has been iden-
tiﬁed here by cryo-EM34. However, other deletions in the BCL10
C-terminus also impaired the tight association of BCL10 to
MALT136. Moreover, on the side of MALT1 it was shown that
the DD as well as the Ig1/Ig2 domains are contributing to the
BCL10 binding in cells33. Thus, we speculate that regions outside
the direct BCL10-MALT1 interface are important for the con-
formation of the CARD and the DD and thus indirectly affect the
interaction. In fact, the crystal structure of the MALT1 DD alone
indicates that in the absence of the Ig1/Ig2 domains the α6 helix
is not kinked, which could certainly prevent BCL10 from
binding37.
Further, we found that MALT1 association to BCL10 is
required for the stimulus-dependent recruitment of BCL10 to
CARD11. In vitro CARD11 and BCL10 form complexes at high
concentrations31,32. Under physiological conditions, however,
only the MALT1-BCL10 complex adopts a conformation that
allows efﬁcient CARD11 association. Mechanistically, MALT1
may either facilitate a BCL10 conformation that promotes
CARD11 binding or wrapping of BCL10 by MALT1 may stabilize
otherwise labile BCL10 core ﬁlaments. Clearly, the cryo-EM
structure reveals stoichiometric binding of BCL10 to MALT1 and
that BCL10 oligomerization is not required for MALT1 associa-
tion, which is in line with the constitutive pre-assembly of BCL10-
MALT1 complexes in cells. Furthermore, BCL10 is decorated with
ubiquitin chains and these BCL10 modiﬁcations have been sug-
gested to activate downstream signaling partially bypassing the
necessity for MALT16,40. However, the absence of a CARD11-
BCL10 binding in MALT1 deﬁcient or BM-I mutant cells indicates
that signaling competent CARD11-BCL10 sub-complexes do not
exist and downstream effects are relying on MALT1 association.
The cellular analyses of structure-guided mutations in the
BCL10 ﬁlament interfaces I and II highlight the necessity of ﬁla-
ment assembly for CARD11 recruitment. Since none of these
mutations affect MALT1 association, it is quite unlikely that they
destroy the overall conformation of the BCL10 CARD or the
interface to CARD11. In line with the modeled CARD11-BCL10
interactions32, we propose that the weak afﬁnity of BCL10
monomers for CARD11 needs to be stabilized by BCL10 oligo-
merization, which augments the afﬁnity by presenting multiple
interfaces. In fact, the data implicate that recruitment of BCL10 to
CARD11 and BCL10 oligomerization are highly interconnected
processes that cannot be uncoupled. Thus, BCL10 oligomerization
may boost an initial low afﬁnity interaction leading to rapid
CBM complex assembly and threshold responses after stimulation.
Furthermore, an interesting aspect regarding the BCL10-
MALT1 core structure is, that BCL10 is degraded upon pro-
longed T-cell stimulation, leading to CBM complex disassembly
and termination of TCR-signaling41,42. Proteasomal degradation
requires unfolding of the proteins and thus the rigidity of BCL10
core ﬁlaments can explain why BCL10 is primarily removed
through selective autophagy and lysosomal degradation41,43.
However, despite the 1:1 stoichiometry of BCL10-MALT1 in the
complex, MALT1 is stable and not degraded after stimulation43.
At present it is unclear how MALT1 is disconnected from the
BCL10 ﬁlaments. MALT1 auto-cleavage at R149 could certainly
release the C-terminal fragment, but there is no evidence for the
appearance of a stabilized DD-truncated form of MALT1 after
stimulation44. The BCL10 C-terminus is most likely ﬂexible and
was not visible in the cryo-EM map, but interestingly hyper-
phosphorylation of BCL10 in this Ser/Thr-rich region impairs
binding to MALT136. Thus, post-translational modiﬁcations of
BCL10 or MALT1 may be involved in the release of MALT1 to
separate it from removal by autophagy.
Despite the lower resolution in the outer region of the 29 nm
wide BCL10-MALT1 ﬁlaments, the cryo-EM map depicts how the
C-terminal MALT1 domains are emanating from the BCL10-
MALT1 DD core ﬁlament forming a ‘paddle wheel-like’ shape. In
spite of the moderate resolution of the map of the outer regions in
the BCL10-MALT1 complex, the current data allows us to pro-
vide a model in which MALT1 C-terminal region covering the
Ig2-paracaspase-Ig3 domain is ﬂexibly attached to the BCL10-
MALT DD core ﬁlaments. The ﬂexibility and positioning of the
individual MALT1 molecules in the ﬁlament periphery provides a
platform for the recruitment of mediators like TRAF6 to foster
NF-κB signaling38. Further, mono-ubiquitination, substrate
binding and paracaspase domain dimerization will promote
protease activation39,45. Future studies must elucidate the
mechanism of MALT1 protease activation in the complex and
how the BCL10-MALT1 platform integrates factors like TRAF6,
TAK1 and NEMO/IKKβ to initiate downstream processes.
Methods
Expression and puriﬁcation. Human MALT1 isoform B amino acids T29 to G722
and the V81R mutant of this construct were cloned by Nde1 and Not1 restriction
sites into a modiﬁed pET28a vector (Novagen), containing a N-terminal PreScis-
sion Protease (GELifeSciences) cleavable 8 × -His-tag sequence (Supplementary
Table 2). Human BCL10 wt and the respective R36E, R42E, R49E mutants were
cloned into pGEX-6P-2 vector (GELifeSciences) using BamH1 and Xho1 restric-
tion sites (Supplementary Table 3)36. The corresponding plasmids were co-
transformed in Escherichia coli Rosetta™ (DE3) strain (Novagen), protein expres-
sion was induced by addition of 0.2 mM IPTG and performed overnight at 18 °C.
Cells were resuspended in lysis buffer containing 50 mM Hepes pH= 7.5, 200 mM
NaCl, 7 mM Imidazol and 4 mM β-mercaptoethanol. Cells were lysed by sonication
and clariﬁed by centrifugation. The BCL10-MALT1 complex was further puriﬁed
by Ni-NTA afﬁnity chromatography (Qiagen) using the lysis buffer containing
250 mM Imidazol as elution buffer. Subsequently, the NiNTA elution fraction was
loaded on a Glutathion-sepharose column (GE-Healthcare) and eluted with lysis
buffer containing 20 mM reduced Glutathion. Size exclusion chromatography
Fig. 5 Functional analyses of the MALT1-BCL10 interface in Jurkat and murine CD4 T-Cells. a BCL10 KO Jurkat T-cells were lentivirally reconstituted with
BCL10 wt or BM-I mutant L104R constructs. After 20min P/I stimulation CBM complex formation was investigated by BCL10-IP. Asterisk indicates non-
speciﬁc cross-reactivity of the BCL10 antibody. b, c MALT1 KO Jurkat T-cells were lentivirally reconstituted with MALT1 wt or BM-I mutant constructs
V81R (b) or L82D (c). P/I stimulation and CBM complex formation was investigated as in (a). d–h NF-κB signaling (d, f, h) and MALT1 protease activation
(e, g, h) in BCL10 (d, e) or MALT1 (f–h) BM-I mutant reconstituted Jurkat T-cells after P/I treatment was analyzed by Western Blot (IκBα phosphorylation
and degradation) and NF-κB-DNA binding studies (EMSA). Induction of MALT1 protease activity was monitored by cleavage of MALT1 substrates in WB
as indicated. i Expression of MALT1 wt and BM-I mutant (V81R) was determined by WB after enrichment of infected murine MALT1−/− CD4 T-cells. j
MALT1−/− CD4 T-cells transduced with MALT1 wt or BM-I mutant were stimulated for 30min with P/I. IκBα expression and degradation were measured
by FACS and transduced cells were gated by co-staining of Thy1.1 (Supplementary Fig. 6a). k, l MALT1−/− CD4 T-cells transduced as in (j) and stimulated
for 5 h with P/I (k) or anti-CD3/CD28 (l). Intracellular IL-2 production was determined by FACS and transduced cells were gated by co-staining of Thy1.1
(Supplementary Fig. 6b)
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(S200 26/60, GE-Healthcare) was performed to separate BCL10-MALT1 complex
fractions. Size exclusion buffer contained 25 mM Hepes pH= 7.5, 200 mM NaCl
and 2 mM β-mercaptoethanol.
MALT1 activity assay. The MALT1 cleavage assay was performed with 500 nM or
10 µM of BCL10-MALT1 ﬁlaments, GST-BCL10-MALT1 species, and MALT1
V81R mutant. Protein samples were incubated in 384-well non-binding micro-
plates and 20 μM of the MALT1 substrate Ac-LRSR-AMC was added. After 2 min
incubation at 30 °C, the ﬂuorescence of cleaved AMC was measured over 1 h by a
Synergy 2 Microplate Reader (Biotek, US). The MALT1 protease activity is
represented in relative ﬂuorescence units and data from at least three independent
experiments were used.
BCL10-MALT1 complex formation analysis. The BCL10-MALT1 complex frac-
tions were pooled and concentrated to 0.5 μM. Filament formation was initialized
by addition of PreScission protease (GE Healthcare) in equimolar amounts.
Polymerization of BCL10-MALT1 species was monitored by dynamic light scat-
tering (Viscotek 802 DLS) as a function of time over 100 min. Higher order species
(above 104 nm) were excluded from data evaluation. Data was analyzed by the
OmniSIZE 3.0 software package (Viscotek).
BCL10-MALT1 complex preparation for cryo electron microscopy. BCL10-
MALT1 complex fractions were concentrated stepwise to 1 mg/ml. Higher mole-
cular species formation was monitored for each concentration step by dynamic
light scattering (Viscotek 802 DLS). Filament formation was initialized by addition
of equimolar amounts of PreScission Protease (GE Healthcare) and performed
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Fig. 6 Structural organisation of additional MALT1 domains in framework of the BCL10-MALT1 ﬁlament. a, b EM density map of the well-ordered inner core
of the BCL10-MALT1 ﬁlament shown together with the atomic model of BCL10 (blue) and MALT1 DD (orange) as built in the 4.9 Å density map (map
sharpening B-factor applied: −200 Å2). c, d Reconstructed density map ﬁltered to 8 Å indicates the orientation of the MALT1 Ig1 domain shown as ribbon
and colored yellow (B-factor applied: −100 Å2). e, f Paddle-wheel like architecture of the BCL10-MALT1 ﬁlament revealed by the EM-density ﬁltered to 25
Å (B-factor applied: 0 Å2)
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overnight at 12 °C. Analytical size exclusion chromatography (S200 5/150 GL) was
performed to separate BCL10-MALT1 ﬁlaments from non-oligomerized protein.
Directly before blotting Octyl-beta-Glucoside was added to the selected size
exclusion fraction with a ﬁnal concentration of 0.001%. 4.5 µl of the BCL10-
MALT1 sample was applied on glow-discharged R1/2 grids (Quantifoil Cu R1/2,
300 mesh). The grids were blotted for 3 s at 95 % humidity and 15 °C and plunge-
frozen in liquid ethane using a Leica Plunger (FEI).
Cryo electron microscopy data collection. Cryo-EM images of the BCL10-
MALT1 complex were collected on a 200 keV Talos Arctica microscope equipped
with a Falcon III detector (FEI). In total 662 micrographs were collected auto-
matically using the EPU software (FEI). Micrographs were acquired in nano-probe
mode using 49 movie frames with a dose of ~2 electrons/Å2/frame resulting in a
total dose of 98 electrons per Å2 at a pixel size of 1.002 Å.
Helical reconstruction. In order to obtain both a higher resolution map of the core
of the BCL10-MALT1 ﬁlaments, and a lower resolution map of the entire assembly,
we performed two 3D reﬁnements, varying the diameter limitation used during
reﬁnement, and the total dose used prior to particle extraction. For the higher
resolution map, the frames 2 to 7 (total dose ~14 electrons/Å2) out of a total of 49
frames were motion-corrected and dose-weighted using MotionCor246, while for
the lower-resolution map, the frames 2 to 16 (total dose ~32 electrons/Å2) were
processed. The low dose dataset was used to determine the helical symmetry and to
obtain the map of the BCL10-MALT1DD ﬁlament core, while the higher dose
dataset enabled to get information about the periphery of the ﬁlaments.
For both datasets, the defocus estimation was performed with CTFFIND/
CTFTILT47. In total, 2618 straight sections of ﬁlaments were boxed manually using
the e2helixboxer submodule of EMAN248 from a selected subset of 370
micrographs. The average length of picked BCL10-MALT1 ﬁlament sections was
~756 Å and the total length ~0.2 mm (Supplementary Table 1). All subsequent
processing steps were performed in the helical reconstruction software package
SPRING49. In total 25,576 segments were extracted using a segment size of 500 Å
and segment step size of 30 Å. For 2D classiﬁcation and initial symmetry
estimation, phase-ﬂipped, verticalized segments were extracted from the low dose
dataset, whereas for symmetry reﬁnement and 3D reconstruction, convolved, non-
rotated segments were used. The sum of the power-spectra of all verticalized
segments was calculated using Segmentexam module, conﬁrming the helical nature
of the specimen. Helical parameters were determined as follows. First, 40 class
averages were obtained using k-means clustering algorithm from SPARX50 as
implemented in the Segmentclass module. Class averages showed a repetition of
the projection pattern along the helical axis every ~126 Å, suggesting that this
distance was a close estimate of the repeat c. The sum of the power spectra of 2D
class averages padded in 1080*1080 pixels boxes and showing the biggest number
of layer lines (11 class-averages) was then calculated for symmetry estimation.
Layer lines are positioned at multiples of ~1/126 Å−1, conﬁrming the initial
estimation of the repeat (Supplementary Fig. 7a). A strong layer line (l= 7) with a
ﬁrst intensity maximum near the meridian (Bessel order n= 1) was attributed to
the pitch P, with a height of 1/18 Å−1. Worthy of note, other CARD domain
assemblies have their layer line corresponding to the pitch at position l= 951.
Therefore, the structure repeats after 7 helix turns and the possible solutions of the
number of units s are such that s*7= u; u being the integer corresponding to the
number of units in the repeat c. Given a range of s between 1.5 and 4.5, as
estimated from the size of the subunit, the pitch, and the reported symmetries for
CARD assemblies in the literature, we deﬁned a range of possible values for u of 10
to 32. For each u in this range, we calculated all ratios s= u/7, excluding the
solutions with s integer, as those solutions would correspond to a helix with a
repeat c equal to P. Retained solutions have layer line heights matching those
observed in the experimental power spectra, but have different predicted Bessel
orders n for each layer line. The compatibility between predicted n’s and
experimental meridional distance of ﬁrst intensity maximum along layer lines in
the sum of power spectra was then assessed, to narrow down the number of
possible symmetries. These symmetries were further used to generate low-
resolution 3D models from the 2D class-average with most signal in its power
spectrum (Supplementary Fig. 7b), with the module Segclassreconstruct. Only one
symmetry, with s= 3.571 units/turn, gave a plausible model in terms of density
distribution (Supplementary Fig. 7c). This symmetry and the corresponding 47low-
resolution model were used as input for 3D reﬁnement using Segmentreﬁne3D,
with a limitation of diameter of 210 Å applied on the reference model at each
iteration, giving an initial map with an average resolution of 5.7 Å. Comparison
with existing CARD domain atomic models showed that the helix was left-handed.
Importantly, when a cylinder was used as initial model instead of the model
constructed from the class-average, the reﬁnement couldn’t converge to a correct
3D structure. The helical symmetry was further reﬁned using segreﬁne3dgrid
module, still using a diameter of 210 Å, to a pitch of 18.15 Å and 3.571 subunits per
turn, corresponding to a helical rise of 5.083 Å and a helical twist of −100.81°.
Using the reﬁned symmetry parameters and a strong segment selection based
on geometrical restraints49,52 such as calculated ﬁlament straightness (60% of
straightest ﬁlaments kept) and forward x-shift difference (limited to 6 Å), the ﬁnal
map of the ﬁlament core was obtained using a reﬁnement diameter of 210 Å, with
8591 segments corresponding to 51,546 asymmetric units after symmetrization.
The overall resolution of this map estimated at Fourier shell correlation (FSC)
cutoff of 0.143 was 4.9 Å (Supplementary Table 1, Supplementary Fig. 8). This map
was used as an initial model for the processing of the higher dose dataset using an
analogous approach, but this time with the symmetry parameters were kept ﬁxed
and a higher reﬁnement diameter of 290 Å was used for visualization of the less
ordered ﬁlament exterior. Selected 8412 segments corresponding to 50,472
asymmetric units after symmetrization resulted in a map of the whole BLC10-
MALT1 assembly with an overall resolution of 5.9 Å.
Both 4.9 Å and 5.9 Å resolution raw half maps were symmetrized and used to
estimate the local resolution (Supplementary Fig. 8b) and the B-factor using
relion_postprocess. Additionally, in order to assess the resolution of each region of
the maps (Bcl10, MALT1 DD, MALT1 Ig1-Ig2-paracaspase domains) FSC curves
were calculated between half maps within smooth cylinder masks of various
diameters of 0–83 Å, 83–140 Å, and 140–260 Å (Supplementary Fig. 8a). The ﬁnal
higher resolution map of ﬁlament core (Fig. 1) used for model building was post-
processed using 3Dinspect module in Spring with a b-factor of −200 Å−2 and a
resolution cutoff of 4.9 Å, whereas the lower resolution map of the entire assembly
was post-processed with various resolution cut-off and sharpening, as indicated in
Fig. 4.
Model building and reﬁnement. The BCL10 CARD domains and MALT1 DD
were built using Coot53. To this end, BCL10 was generated by ﬂexible ﬁtting of a
homology model created by the program Phyre2 54 and under consideration of the
BCL10 CARD domain NMR structure (pdb ID: 2MB9). The MALT1 DD was built
in the EM density using the related crystal structure (pdb ID: 2G7R) as well as a
homology model based on the APAF CARD domain (pdb ID: 2YGS) structure
prepared with Modeller55. The ﬁnal model was reﬁned with PHENIX real-space
reﬁnement56. The similarity of the reﬁned model of BCL10 CARD with the
unsharpened, unﬁltered map of the ﬁlament core was assessed by FSC, after helical
symmetrization of the model and calculation of a density map with a voxel size of
1.002 Å using Chimera. Similarly, the reﬁned model and the previously deposited
model PDB: 6BZE, were compared to the EMDB entry EMD-7314. Final ﬁgures
were generated with UCSF Chimera and PyMol57,58.
Antibodies and DNA constructs. The following antibodies were used for
immunoprecipitation (IP), Western Blot (WB), and ﬂuorescence activate cell
sorting (FACS). WB was done at a dilution of 1:1000 except when otherwise stated.
Anti-HA (3F1 (WB), obtained from E. Kremmer); anti-CARD11 (1D12), anti-IκBα
(L35A5, FACS 1:50), anti-p-IκBα (5A5) (all Cell Signaling Technology); anti-
FLAG-M2 (F3165, Sigma-Aldrich, WB 1:10000, IP 1 µl); anti-hCD2-APC (RPA-
2.10, eBioscience, FACS 1:200); anti-BCL10 (EP606Y, Abcam, for endogenous
BCL10); anti-BCL10 (C-17, IP 2.5 µl) and H-197 (WB for strep-tagged BCL10);
anti-MALT1 (B12), anti-β-Actin (C4; WB 1:10000), anti-CYLD (E10) (all Santa
Cruz Biotechnology); anti-HOIL-1 (S150D, MRC PPU Reagents); Regnase-1
(604421, R&D; WB 1:500); horseradish peroxidase (HRP)-conjugated secondary
antibodies (Jackson ImmunoResearch); anti-mouse IgG1-FITC (A85-1, BD, FACS
1:100), anti-IL-2-APC (JES6-5H4, eBioscience; FACS 1:100) and anti-Thy1.1-APC-
Cy7 (HIS51, eBioscience; FACS 1:200) were used. For Jurkat T-cell stimulation
anti-human CD3 and CD28 from mouse were used in the presence of anti-murine
IgG1 and IgG2a (all BD Pharmingen). For CD4 T-cell stimulation anti-murine
CD3 and CD28 (BD Pharmingen) from hamster were used in the presence of plate-
bound rabbit anti-hamster (Jackson ImmunoResearch). Oligonucleotides for
EMSAs were: H2K (fw: 5′-GATCCAGGGCTGGGGATTCCCCATCTCCACAGG-
3′, rev: 5′-GATCCCTGTGGAGATGGGGAATCCCCAGCCCTG-3′), OCT1 (fw:
5′-GATCTGTCGAATGCAAATCACTAGAA-3′, rev: 5′-GATCTTCTAGT-
GATTTGCATTCGACA-3′).The following DNA constructs were used: 3xFlag and
HA tagged MALT1B and BCL10 cDNAs were cloned in the pEF backbone vector
(Invitrogen) or pHAGE-ΔCD2-T2A (lentiviral transduction)59 or pMSCV-IRES-
Thy1.1 (retroviral transduction)4.
Cell culture and stimulation. Cells were grown in DMEM (HEK293, HEK293T
(both DSMZ), Phoenix-ECO (ATCC) or RPMI 1640 (Jurkat T-cells; veriﬁed by
DSMZ) medium supplemented with 10% fetal calf serum and 100 U/ml penicillin/
streptomycin (P/S) (all Life Technologies). HEK293 cells were transfected using
standard calcium phosphate precipitation protocols. For P/I stimulation of Jurkat
T-cells, 200 ng/ml PMA and 300 ng/ml Ionomycin were applied. For CD3/CD28
co-ligation, 0.3 µg anti-CD3 and 1 µg anti-CD28 antibody was used in the presence
of 0.5 µg rat anti-mouse IgG1 and IgG2a.
Generation and reconstitution of KO Jurkat T-cells. Bicistronic expression
vector px458 expressing Cas9 and sgRNA60,61 was digested with BbsI and the
linearized vector was gel puriﬁed. Targeting oligonucleotides and generation of
MALT1-deﬁcient Jurkat T-cells has been described38. For BCL10 two oligonu-
cleotides targeting sites and ﬂanking exon1 (5′AGTGAGGTCCTCCTCGGTGA 3′/
5′TTCCGCTTTCGTCTCCCGCT 3′ (Supplementary Fig. 4a) were cloned. Jurkat
T-cells (4 × 106) were electroporated (220 V and 1000 µF) using a Gene pulser X
(Biorad) with px458 plasmids (Addgene #48138; gift F. Zhang) containing sgRNA
targeting BCL10 and EGFP expression cassette. Twenty-four hours after electro-
poration, EGFP-positive cells were sorted using a MoFlo sorting system (Beckman
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Coulter). Isolation of clonal cell lines was achieved by serial dilutions and was
followed by an appropriate expansion period. KO cell clones were initially iden-
tiﬁed by anti-BCL10 staining by Western Blot. Clones lacking protein expression
were genotyped by genomic PCR using intronic primers ﬂanking targeting sides.
For reconstitution, MALT1 isoform B and BCL10 cDNAs were linked to a C-
terminal Flag-Strep-Strep tag and hΔCD2 by a co-translational processing site
T2A59 and introduced into pHAGE lentiviral expression plasmids. Lentivirus was
produced by transfecting HEK293T cells with 1.5 μg psPAX2 (Addgene #12260;
gift D. Trono), 1 μg pMD2.G (Addgene #12259; gift D. Trono) and 2 μg transfer
vector. Seventy-two hours after transfection, lentivirus encoding MALT1 and
BCL10 were collected, ﬁltrated and in the presence of 8 μg/ml polybrene added to
MALT1 and BCL10 KO Jurkat T-cells (5 × 105 cells), respectively. After 24 h, virus
was replaced by RPMI medium. FACS analysis using an Attune Flow Cytometer
(Applied Biosystems) revealed >95% ΔCD2-positive cells after one week in culture.
Puriﬁcation and analysis of murine MALT1−/− CD4+T-cells. CD4+ T-cells
were MACS-puriﬁed from spleen and lymph nodes of MALT1−/− mice (MAL-
T1tm1a(EUCOMM)Hmgu; ES cell clone HEPD0671_C08) and stimulated with plate-
bound anti-CD3/CD28 antibodies for 48 h. Retroviruses were produced in Phoenix
cells transfected with pMSCV retroviral transfer vectors carrying human MALT1-
FlagStrepII constructs and Thy1.1 (separated by internal ribosome entry site (IRES)
sequence) and viruses were collected after 48 and 72 h. CD4+ T-cells were incu-
bated for 6 h with retroviral supernatant supplemented with Polybrene (8 µg/ml)
and then washed and cultured in RPMI medium supplemented with IL-2 (20 U/
ml),10% heat-inactivated FCS, 1% P/S, 1% NEAA (Life Technologies), 1% HEPES,
1% L-glutamine, 1% sodium pyruvate (Life Technologies) and 0.1% b-
mercaptoethanol for 3 days before analysis. Infection efﬁciencies between 25 and
50% were achieved.
For IκBα degradation, cells were stimulated for 30 min with PMA (200 nM) and
Ionomycin (300 nM), ﬁxed with 2% paraformaldehyde and stained for Thy1.1.
After permeabilization (0.1% saponine), cells were stained using mouse anti-IκBα
antibody (L35A5, CST) and anti-mouse IgG1 FITC (BD). For determination of
intracellular IL-2, cells were rested for 12 h and then stimulated with P/I or plate-
bound anti-CD3/CD28 (0.5 µg/ml CD3 and 1 µg/ml CD28) antibodies for 5 h in
the presence of Brefeldin A. After ﬁxation and permeabilization, cells were stained
with anti-IL-2 APC antibody (JES6-5H4, eBioscience). FACS analyses were
performed using an Attune Flow Cytometer (Applied Biosystems) and analyzed
with FlowJo Software (Treestar).
Cell lysis and cellular binding studies. For cellular analyses Jurkat T-cells (2–3 ×
106) were lysed in co-immunoprecipitations (co-IP) buffer (25 mM HEPES (pH
7.5), 150 mM NaCl, 0.2% NP-40, 10% glycerol, 1 mM DTT, 10 mM sodium
ﬂuoride, 8 mM β-glycerophosphate, 300 μM sodium vanadate and protease inhi-
bitor cocktail). For monitoring CBM complex formation after IP or StrepTactin
pulldown (ST-PD), Jurkat T-cells (1–3 × 107) were lysed in co-IP buffer. Lysate
controls were taken up in 4xSDS-loading buffer and boiled for 5 min at 95 °C. IP
was carried out using anti-BCL10 C-17 (2.5 µl) or anti-Flag-M2 (1 µl) antibodies
overnight at 4 °C. Afterwards Protein G Sepharose (15 µl 1:1 suspension) was
administered for 1–2 h at 4 °C to bind antibodies. StrepII-tagged were pulled down
(ST-PD) with Strep-Tactin Sepharose (15 µl 1:1 suspension) at 4 °C overnight. For
co-IP and ST-PD beads were washed with co-IP buffer and boiled after adding of
22 µl 2x SDS loading buffer. Lysates and precipitated proteins were separated by
SDS-PAGE and analyzed by Western blot.
Western blotting. Transfer onto PVDF-membranes was performed using elec-
trophoretic semi-dry blotting system. PVDF-membranes were blocked with 5%
BSA for 1 h at RT and before primary antibody (indicated above, dilution 1:1000 in
2.5% BSA/PBS-T) were incubated overnight at 4 °C. Membranes were washed in
PBS-T and HRP (horse radish peroxidase)-coupled secondary antibodies (indicated
above, 1:7000 in 1.25% BSA in PBS-T; 1 h, RT) were used for detection. HRP was
visualized by enhanced chemiluminescence (ECL) with LumiGlo reagent (Cell
Signaling Technologies) according to the protocol of the manufacturer. Images
were cropped for presentation and full size images are presented in Supplementary
Fig. 9.
Electrophoretic mobility shift assay. Electrophoretic mobility shift assays
(EMSAs) were carried out using double-stranded NF-κB or OCT1 binding
sequences (H2K or OCT1 oligonucleotides; see reagents) which were radioactively
labeled using [α-32P] dATP in a Klenow Fragment (NEB) reaction. Whole cell
lysates (3–6 µg) were incubated for 30 min at RT with shift-buffer (HEPES pH 7.9
(20 mM), KCl (120 mM), Ficoll (4%)), DTT (5 mM), BSA (10 µg) and poly-dI-dC
(2 µg, Roche) and radioactive probe (10,000–20,000 cpm) to detect DNA binding of
transcription factors. Samples were run on a 5% polyacrylamide gel in TBE buffer
and exposed to autoradiography after vacuum-drying. Images were cropped for
presentation and full size images are presented in Supplementary Fig. 9.
Data availability. The electron density reconstruction and ﬁnal model were
deposited with the EM Data Base (accession codes EMD-0013, PDB ID 6GK2).
Other data are available from the corresponding authors upon reasonable request.
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